GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (FRA:ONMA) » Definitions » Forward PE Ratio

OncoSec Medical (FRA:ONMA) Forward PE Ratio : 0.00 (As of Oct. 31, 2024)


View and export this data going back to 2015. Start your Free Trial

What is OncoSec Medical Forward PE Ratio?

OncoSec Medical's Forward PE Ratio for today is 0.00.

OncoSec Medical's PE Ratio without NRI for today is 0.00.

OncoSec Medical's PE Ratio (TTM) for today is 0.00.


OncoSec Medical Forward PE Ratio Historical Data

The historical data trend for OncoSec Medical's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical Forward PE Ratio Chart

OncoSec Medical Annual Data
Trend 2022-04
Forward PE Ratio
9.01

OncoSec Medical Quarterly Data
Forward PE Ratio

Competitive Comparison of OncoSec Medical's Forward PE Ratio

For the Biotechnology subindustry, OncoSec Medical's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoSec Medical's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoSec Medical's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where OncoSec Medical's Forward PE Ratio falls into.



OncoSec Medical Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


OncoSec Medical  (FRA:ONMA) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


OncoSec Medical Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoSec Medical Business Description

Traded in Other Exchanges
N/A
Address
24 North Main Street, Pennington, NJ, USA, 08534
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

OncoSec Medical Headlines

No Headlines